HER2/NEU NEGATIVE
Clinical trials for HER2/NEU NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new HER2/NEU NEGATIVE trials appear
Sign up with your email to follow new studies for HER2/NEU NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat breast cancer: drug combo shows promise
Disease control CompletedThis study tested a drug called alisertib, either alone or combined with the hormone therapy fulvestrant, in 96 postmenopausal women with advanced breast cancer that had stopped responding to standard hormone treatments. The goal was to see if these treatments could shrink tumors…
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo offers Surgery-Free option for elderly breast cancer patients
Disease control CompletedThis study tested a combination of two hormone-blocking drugs (fulvestrant and palbociclib) in 14 elderly patients with hormone-sensitive breast cancer who either could not undergo surgery due to frailty or chose not to have it. The goal was to see if this drug pair could control…
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo shows promise for older breast cancer patients
Disease control CompletedThis study looked at how well older adults (70+) with a common type of advanced breast cancer tolerate a combination of the targeted drug palbociclib and hormone therapy (letrozole or fulvestrant). The goal was to understand side effects and find factors beyond age that might pre…
Matched conditions: HER2/NEU NEGATIVE
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 06, 2026 16:01 UTC